Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform

17 Oct 2020

Abstract excerpt

The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. The Modified Vaccinia Ankara (MVA) vector system is being explored as a platform for development of multiple vaccines. This paper reviews the molecular and biological features specifically of the MVA-BN vector system, followed by a template...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacillus and Francisella bacterial research
Share to Poxvirus research and outbreaks
Share to Viral Infections and Outbreaks Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33077299
DOI: 10.1016/j.vaccine.2020.08.050

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platformPMID 33077299Read ↗

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessmentSemantic proximity Read ↗

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessmentSemantic proximity Read ↗

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessmentSemantic proximity Read ↗

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Zaire ebolavirus, Sudan ebolavirus, Marburg and Lassa virusesSemantic proximity Read ↗

Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive ReviewSemantic proximity Read ↗

MVA and NYVAC as Vaccines against Emergent Infectious Diseases and CancerSemantic proximity Read ↗

Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19Semantic proximity Read ↗

Simultaneous broad protection against Ebola Sudan, Marburg and Lassa viruses conferred by a DNA primed MVA-vectored multivalent vaccineSemantic proximity Read ↗

Challenges, Progress, and Pathways to Equitable ACCESS in Lassa Fever Vaccine DevelopmentSemantic proximity Read ↗

A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya virusesSemantic proximity Read ↗

Poxviral promoters for improving the immunogenicity of MVA delivered vaccinesSemantic proximity Read ↗

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and SenegalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.